ABSTRACT
Importance Interleukin-6 signal blockade has shown preliminary beneficial effects in treating aberrant host inflammatory response against SARS-CoV-2 leading to severe respiratory distress.
Objective to describe the effect of off-label intravenous use of Sarilumab in patients with severe SARS-CoV-2-related pneumonia.
Design Observational clinical cohort study.
Setting Fondazione Policlinico Universitario A. Gemelli IRCCS as Italian Covid reference center.
Participants Patients with laboratory-confirmed SARS-CoV-2 infection and respiratory distress with PaO2/FiO2 ratio<300 treated with Sarilumab between March 23rd – April 4th, 2020. Date of final follow-up was April 18, 2020.
Main outcomes and measures We describe the clinical outcomes of 53 patients with SARS-CoV-2 severe pneumonia treated with intravenous Sarilumab in terms of pulmonary function improvement or Intensive Care Unit (ICU) admission rate in medical wards setting and of live discharge rate in ICU treated patients as well as in terms of safety. Each patient received Sarilumab 400 mg administered intravenously on day 1, with eventual additional infusion based on clinical judgement, and was followed for at least 14 days, unless previously discharged or dead. No gluco-corticosteroids were used at baseline.
Results Of the 53 SARS-CoV-2pos patients receiving Sarilumab, 39 (73.6%) were treated in medical wards (66.7% with a single infusion) while 14 (26.4%) in ICU (92.6% with a second infusion). The median PaO2/FiO2 of patients in the Medical Ward was 146(IQR:120-212) while the median PaO2/FiO2 of patients in ICU was 112(IQR:100-141.5), respectively.
Within the medical wards, 7(17.9%) required ICU admission, 4 of whom were re-admitted to the ward within 5-8 days. At 19 days median follow-up, 89.7% of medical inpatients significantly improved (46.1% after 24 hours, 61.5% after 3 days), 70.6% were discharged from the hospital and 85.7% no longer needed oxygen therapy. Within patients receiving Sarilumab in ICU, 64.2% were discharged from ICU to the ward and 35.8% were still alive at the last follow-up. Overall mortality rate was 5.7% after Sarilumab administration: 1(2.5%) patient died in the Medical Ward whilst 2(14.2%) patients died in ICU, respectively.
Conclusions and relevance IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical benefit and good safety.
Question SARS-CoV-2 infection remains a disease with many unknown aspects for which there are no therapies with proven efficacy. To date, it is recognized that COVID-19 disease may lead to the development of a cytokine storm for which drugs as IL-6R inhibitors may have beneficial effect.
Findings In this observational clinical study, we reported the efficacy and safety of intravenous Sarilumab use in SARS-CoV-2 severe pneumonia with a global resolution rate of 83.0% (89.7% in medical wards and 64.3% in ICU) and an overall mortality rate of 5.7%.
Meaning IL-6R-inhibition is an effective approach for severe SARS-CoV-2 pneumonia and intravenous Sarilumab is a promising treatment approach leading to an important clinical benefit and good safety in the short term.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N.A.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email Addresses of the contributing authors: elisa.gremese{at}unicatt.it, antonella.cingolani{at}policlinicogemelli.it, silvialaura.bosello{at}policlinicogemelli.it, stefano.alivernini{at}unicatt.it, barbara.tolusso{at}policlinicogemelli.it, perniolasi{at}hotmail.it, francesco.landi{at}unicatt.it, maurizio.pompili{at}unicatt.it, rita.murri{at}policlinicogemelli.it, angelo.santoliquido{at}policlinicogemelli.it, matteo.garcovich{at}policlinicogemelli.it, michela.sali{at}unicatt.it, gennaro.depascale{at}policlinicogemelli.it, maurizio.gabrielli{at}policlinicogemelli.it, federico.biscetti{at}policlinicogemelli.it, massimo.montalto{at}policlinicogemelli.it, alberto.tosoni{at}policlinicogemelli.it, giovanni.gambassi{at}unicatt.it, gianludovico.rapaccini{at}unicatt.it, amerigo.iaconelli{at}policlinicogemelli.it, lorenzo.zileridalverme{at}policlinicogemelli.it, luca.petricca{at}policlinicogemelli.it, annalaura.fedele{at}policlinicogemelli.it, marcomaria.lizzio{at}policlinicogemelli.it, enrica.tamburrini{at}unicatt.it, gerlando.natalello91{at}gmail.com, laura.gigate.91{at}gmail.com, dariobrunomd{at}gmail.com, lucreziaverardi{at}gmail.com, eleonora.taddei{at}policlinicogemelli.it, angelo.calabrese{at}policlinicogemelli.it, francesco.lombardi{at}policlinicogemelli.it, roberto.bernabei{at}unicatt.it, roberto.cauda{at}policlinicogemelli.it, francesco.franceschi{at}policlinicogemelli.it, raffaele.landolfi{at}unicatt.it, luca.richeldi{at}unicatt.it, maurizio.sanguinetti{at}policlinicogemelli.it, massimo.fantoni{at}unicatt.it, massimo.antonelli{at}policlinicogemelli.it, antonio.gasbarrini{at}unicatt.it
Data Availability
N.A.
